SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Ray Charles Synthetic CCD
| Patient | Ray Charles |
|---|
| Date of birth | 1960-09-23 |
|---|
| Identifiers | MRN HR-ML009-SYN; SSN (made up) 000-09-5561 |
|---|
| Document date | 2026-11-01 |
|---|
| Author | Gloria Fenwick, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Reason for Visit
Establishing primary care: accessible care for a blind adult, recovery-oriented review, and depression and safety screening. Concerns: He wants his records and instructions in a form he can read himself, without having to rely on someone else; He wants any future pain treated without putting his long recovery at risk. [S]
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Medications
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response, and call 911 | Nasal route | 2026-03-03 | active | S |
Procedures
| Procedure | Dates | Status | Evidence |
|---|
| Ophthalmic examination of the blind eyes for comfort and complications | 2026-03-31 to 2026-03-31 | completed | S |
| Advance care planning conversation, about 20 minutes | 2026-10-06 to 2026-10-06 | completed | S |
Immunizations
| Date | Vaccine | Status | Evidence |
|---|
| 2025-10-20 | High-dose influenza vaccine, 2025-2026 season | completed | S |
| 2026-10-06 | High-dose influenza vaccine, 2026-2027 season | completed | S |
| 2026-10-06 | Pneumococcal conjugate vaccine PCV20 | completed | S |
Past Medical History
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|
| 1937 | Gradual loss of sight from about age five; blind by age seven; schooled at the Florida School for the Deaf and Blind | D (CLM-0003) |
| 1937 | Cause of the childhood blindness never diagnosed, by his own account; congenital juvenile glaucoma is the cause most often suggested | R (CLM-0004) |
| 1965 | Heroin addiction from the late 1940s, publicly admitted after an arrest in 1964; stopped in 1965 after rehabilitation at a California sanitarium | D (CLM-0005, CLM-0006) |
Family History
| Relative | Condition | Age at death | Evidence |
|---|
| mother | Died in 1945; cause not recorded in the cited source | | D (CLM-0007) |
| brother | Younger brother died by drowning in early childhood | | D (CLM-0007) |
Health Concerns
| Concern | Status | Evidence |
|---|
| He wants his records and instructions in a form he can read himself, without having to rely on someone else | active | S |
| He wants any future pain treated without putting his long recovery at risk | active | S |
Assessment
- Blindness of both eyes since childhood, no light perception; cause never diagnosed: active, confirmed [S]
- Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment: active, confirmed [S]
Most recent measures: Hemoglobin [Mass/volume] in Blood 14.2 on 2026-03-03; Sodium [Moles/volume] in Serum or Plasma 139 on 2026-03-03; Potassium [Moles/volume] in Serum or Plasma 4.2 on 2026-03-03; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 2026-03-03; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 84 on 2026-03-03; Glucose [Mass/volume] in Serum or Plasma 94 on 2026-03-03; Calcium [Mass/volume] in Serum or Plasma 9.4 on 2026-03-03; Cholesterol [Mass/volume] in Serum or Plasma 186 on 2026-03-03; Cholesterol in HDL [Mass/volume] in Serum or Plasma 54 on 2026-03-03; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 110 on 2026-03-03; Triglyceride [Mass/volume] in Serum or Plasma 110 on 2026-03-03; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 2026-03-03; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 2026-09-01; Total score [AUDIT-C] 2 on 2026-10-06; Total score [DAST-10] 0 on 2026-10-06; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-10-06 [S]
Strengths and supports: Recovery supports: purposeful work, long-time colleagues, and friends; has not needed formal recovery services for many years and knows how to reach them [S]
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Blindness of both eyes since childhood, no light perception; cause never diagnosed | active | confirmed |
H54.0X55 | S — Synthetic modern coding of the documented childhood blindness; category 5 (no light perception) is a synthetic grading of what the sources call blindness. |
| Opioid use disorder (heroin), in sustained remission for more than thirty years, without medication treatment | active | confirmed |
F11.21 | S — Synthetic modern coding of the publicly admitted heroin addiction and his documented recovery; listed as an active problem because it is managed at every visit, with remission carried by the code. |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2026-03-03 | Hemoglobin [Mass/volume] in Blood | 14.2 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-03-03 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-03 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-03 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-03 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 84 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-03 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-03-03 | Calcium [Mass/volume] in Serum or Plasma | 9.4 | mg/dL | 8.6-10.3 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol [Mass/volume] in Serum or Plasma | 186 | mg/dL | <=200 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 54 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-03-03 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 110 | mg/dL | <=129 mg/dL | Normal | S |
| 2026-03-03 | Triglyceride [Mass/volume] in Serum or Plasma | 110 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-03-03 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 2026-03-03 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | | | S |
| 2026-03-03 | Total score [AUDIT-C] | 2 | {score} | | | S |
| 2026-03-03 | Total score [DAST-10] | 0 | {score} | | | S |
| 2026-09-01 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | | | S |
| 2026-10-06 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | | | S |
| 2026-10-06 | Total score [AUDIT-C] | 2 | {score} | | | S |
| 2026-10-06 | Total score [DAST-10] | 0 | {score} | | | S |
Social History
- In sustained remission from opioid use disorder: no heroin or other opioid use for more than thirty years, without medication treatment; DAST-10 0 for the past year [S]
- Alcohol: AUDIT-C 2, below the risk threshold; no tobacco use [S]
- Professional musician who still performs and travels; lives in his own home, arranged so that he can move about it independently [S]
- Recovery supports: purposeful work, long-time colleagues, and friends; has not needed formal recovery services for many years and knows how to reach them [S]
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 2026-03-03 | Body height | 178 | cm | S |
| 2026-03-03 | Body weight | 80 | kg | S |
| 2026-03-03 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-03-03 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-03 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-03-03 | Heart rate | 68 | /min | S |
| 2026-03-03 | Respiratory rate | 14 | /min | S |
| 2026-03-03 | Body temperature | 36.7 | Cel | S |
| 2026-03-03 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-31 | Body height | 178 | cm | S |
| 2026-03-31 | Body weight | 80.2 | kg | S |
| 2026-03-31 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 2026-03-31 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-03-31 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-03-31 | Heart rate | 66 | /min | S |
| 2026-03-31 | Respiratory rate | 14 | /min | S |
| 2026-03-31 | Body temperature | 36.6 | Cel | S |
| 2026-03-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-06-02 | Body height | 178 | cm | S |
| 2026-06-02 | Body weight | 79.8 | kg | S |
| 2026-06-02 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-06-02 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-06-02 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-06-02 | Heart rate | 68 | /min | S |
| 2026-06-02 | Respiratory rate | 14 | /min | S |
| 2026-06-02 | Body temperature | 36.7 | Cel | S |
| 2026-06-02 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-01 | Body height | 178 | cm | S |
| 2026-09-01 | Body weight | 80 | kg | S |
| 2026-09-01 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-09-01 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-09-01 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-09-01 | Heart rate | 66 | /min | S |
| 2026-09-01 | Respiratory rate | 14 | /min | S |
| 2026-09-01 | Body temperature | 36.6 | Cel | S |
| 2026-09-01 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-06 | Body height | 178 | cm | S |
| 2026-10-06 | Body weight | 80.4 | kg | S |
| 2026-10-06 | Body mass index (BMI) [Ratio] | 25.4 | kg/m2 | S |
| 2026-10-06 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-06 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-06 | Heart rate | 68 | /min | S |
| 2026-10-06 | Respiratory rate | 14 | /min | S |
| 2026-10-06 | Body temperature | 36.7 | Cel | S |
| 2026-10-06 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
Encounters
| Date | Purpose | Status | Provenance |
| 2026-03-03 | Establishing primary care: accessible care for a blind adult, recovery-oriented review, and depression and safety screening | finished | S |
| 2026-03-31 | Four-week follow-up with ophthalmology consultation for the blind eyes | finished | S |
| 2026-06-02 | Three-month review of recovery, accessibility, and fall prevention | finished | S |
| 2026-09-01 | Six-month review with depression screening and a plan for any future pain | finished | S |
| 2026-10-06 | Subsequent annual wellness visit | finished | S |
Plan of Treatment
| Intervention | Status | Guideline | Provenance |
| Disability-competent care at every visit: introductions and spoken orientation, describing each step of the examination, offering an arm for guiding, and all documents in an accessible electronic format | completed | GL-AAO-VISREHAB-2023 | S |
| Ophthalmology consultation to examine the blind eyes for comfort and complications and to advise on pressure checks and surveillance | completed | GL-AAO-POAG-2025, GL-CMID-2026 | S |
| Recovery-oriented care: ask about cravings, triggers, and any return to use at each visit in a non-judgmental way; naloxone at home and when traveling; recovery supports he can reach; and a written plan for any future pain | completed | GL-SUD-2021, GL-ASAM-OUD-2020 | S |
| Depression screening with the PHQ-9 at intake and at six months, PHQ-2 at the wellness visit, and a safety review with the 988 Suicide & Crisis Lifeline at each visit | completed | GL-CMID-2026, GL-USPSTF-DEP-2023, GL-SUICIDE-2024 | S |
| Medicine labeling: audio labels from the pharmacy, a braille label on the naloxone, and the same pharmacy for every prescription | completed | GL-AAO-VISREHAB-2023 | S |
| Fall prevention: CDC STEADI screen at each visit, keeping the home layout unchanged, and a sighted guide in unfamiliar places | completed | GL-AAO-VISREHAB-2023 | S |
Goals
| Goal | Target | Status | Outcome | Provenance |
| Visit summaries, results, and medicine information delivered in an accessible electronic format, and medicine labels in braille or audio, by the four-week visit | 2026-03-31 | completed | Visit summaries sent as accessible documents; the pharmacy provides audio labels and a braille label on the naloxone | S |
| Naloxone at home and in his travel bag, with a tactile label, and the people he travels with shown how to use it, by the three-month visit | 2026-06-02 | completed | Naloxone in both places; travel staff shown how to use it | S |
| Stay in sustained remission, with no return to opioid use, through six months | 2026-09-01 | completed | No opioid use; DAST-10 0 at intake and no use reported at each visit | S |
| No falls through six months | 2026-09-01 | completed | No falls | S |
| A written plan for any future acute pain or surgery that uses non-opioid treatment first and builds in safeguards if an opioid is ever needed, by the six-month visit | 2026-09-01 | completed | Plan written with him and saved in an accessible format | S |
Functional Status
- Blind since childhood, with no light perception. Independent in all activities of daily living and instrumental activities using nonvisual methods; uses a screen reader and a smartphone voice assistant; uses a sighted guide in unfamiliar places [S]
- Falls: none in the past year and no fear of falling. Timed Up and Go 10 seconds, walking independently along the clinic corridor after a brief spoken orientation; steady gait; no fall in blood pressure on standing (128/78 seated, 126/78 standing) [S]
- Access needs: staff introduce themselves, say when they enter or leave the room, describe each step of the examination before touching him, and offer an arm rather than steering him. All written material as accessible electronic documents his screen reader can read; medicine labels in braille or audio [S]
Mental Status
- Alert and oriented; warm, witty, and engaged; thought process organized; no signs of intoxication or withdrawal [S]
- Mood good; PHQ-9 score 2 with item 9 scored 0; no thoughts of suicide or self-harm [S]
Structured synthetic safety assessment on 2026-03-03: current ideation absent, intent absent, plan absent. Routine outpatient care. Crisis resources, including the 988 Suicide & Crisis Lifeline, given in an accessible electronic format and saved in his phone; safety reviewed at each visit [S]